This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novartis (NVS) Reportedly Looking to Sell Its Business Units
by Zacks Equity Research
Per a Bloomberg report, Novartis (NVS) is considering the sale of its ophthalmology and respiratory franchises.
Ionis (IONS) Inks Deal to Develop Precision Genetic Medicines
by Zacks Equity Research
Ionis (IONS) inks collaboration deal with the gene editing company, Metagenomi, to expand the former's capabilities in delivering precision genetic medicines.
Emergent's (EBS) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Emergent's (EBS) third-quarter 2022 earnings and revenues miss estimates. EBS issues fresh guidance for its CDMO services
ImmunoGen (IMGN) Q3 Loss Wider, Sales Beat, '22 View Up
by Zacks Equity Research
ImmunoGen (IMGN) reports a wider-than-expected loss in third-quarter 2022. Nevertheless, it beat revenue estimates. The company raises its financial guidance for 2022
Incyte's (INCY) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Incyte's (INCY) earnings and revenues fall shy of estimates in the third quarter of 2022. The company tightens Jakafi's full-year net product revenue guidance.
Pharma Stock Roundup: NVS, MRK Report Q3 Earnings JNJ's Tecvayli Gets FDA Nod
by Kinjel Shah
Novartis (NVS) and Merck (MRK) announce Q3 results. FDA approves J&J's (JNJ) multiple myeloma candidate, Tecvayli.
Alnylam's (ALNY) Earnings and Revenues Lag Estimates in Q3
by Zacks Equity Research
Alnylam's (ALNY) earnings and sales fall shy of estimates in the third quarter of 2022. The company maintains its product revenue guidance for 2022.
Novartis (NVS) Q3 Earnings Top, Revenues Miss Estimates
by Zacks Equity Research
Novartis (NVS) reports mixed results for the third quarter as key brands maintain momentum but generic competition remains a drag.
What's in Store for Novartis (NVS) This Earnings Season?
by Zacks Equity Research
Investors will focus on the regular top and bottom-line numbers along with updates on the Sandoz spin-off when Novartis (NVS) reports third-quarter 2022 results.
Novartis' (NVS) Pluvicto Secures Positive CHMP Opinion
by Zacks Equity Research
Novartis (NVS) radioligand therapy Pluvicto gets positive recommendation by the CHMP for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer.
Novartis (NVS) Stock Moves -0.58%: What You Should Know
by Zacks Equity Research
In the latest trading session, Novartis (NVS) closed at $75.57, marking a -0.58% move from the previous day.
Cytokinetics (CYTK) to Continue ALS Study on Reldesemtiv
by Zacks Equity Research
Cytokinetics (CYTK) plans to continue the COURAGE-ALS study on reldesemtiv in patients with amyotrophic lateral sclerosis following DMC recommendation.
Merck (MRK) Posts Positive Results From PAH Drug Study
by Zacks Equity Research
Merck's (MRK) sotatercept meets primary and secondary endpoints in a phase III study in pulmonary arterial hypertension. The drug was added to MRK's pipeline last year.
Gilead (GILD) Up 2.6% in 3 Months: Will the Momentum Continue?
by Zacks Equity Research
Gilead (GILD) is having a good run despite the volatility on a string of positive updates.
GSK's (GSK) Boostrix Gets FDA Nod for Pertussis in Newborns
by Zacks Equity Research
Following FDA approval, GSK's (GSK) Boostrix is the first vaccine in the United States specifically approved during pregnancy to prevent disease in young infants by vaccinating pregnant women.
BioMarin (BMRN) Starts Restructuring Moves to Increase Efficiency
by Zacks Equity Research
BioMarin (BMRN) intends to reduce the existing workforce by nearly 4%. The company plans to use the savings in costs and redirect them toward its operating expenses.
Lilly's (LLY) Diabetes Drug Gets FDA Fast Track Tag for Obesity
by Zacks Equity Research
Eli Lilly (LLY) receives a fast-track designation from the FDA for tirzepatide to treat obesity in adult patients. The company will begin rolling NDA submission later this year.
The Zacks Analyst Blog Highlights Novartis, Lowe's, The Goldman Sachs, Twitter and Xcel Energy
by Zacks Equity Research
Novartis, Lowe's, The Goldman Sachs, Twitter and Xcel Energy are part of the Zacks top Analyst Blog.
Top Research Reports for Novartis, Lowe's & Goldman Sachs
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including Novartis AG (NVS), Lowe's Companies, Inc. (LOW) and The Goldman Sachs Group, Inc. (GS).
GSK's (GSK) PD-1 Inhibitor Drug Meets Lung Cancer Study Goal
by Zacks Equity Research
GSK's (GSK) mid-stage study, evaluating the combination of its cancer drug Jemperli with chemotherapy in non-small cell lung cancer, meets the primary endpoint of objective response rate.
Biohaven (BHVN) Stock Up on Spin-Off Transaction Finalization
by Zacks Equity Research
The newly spun-off Biohaven Ltd. (BHVN) advances a portfolio of non-CGRP pipelines targeting neurological and neuropsychiatric indications.
Can Biogen (BIIB) Navigate Multiple Challenges & Grow Again?
by Zacks Equity Research
Most of Biogen's (BIIB) key drugs are facing declining sales. Despite these challenges, we are hopeful that potential new product launches such as lecanemab, zuranolone and additional biosimilars can help revive growth.
NVS vs. RHHBY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NVS vs. RHHBY: Which Stock Is the Better Value Option?
Is Novartis (NVS) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.